C.M. Bidwell & Associates’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

C.M. Bidwell & Associates’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,490	Closed	-$34.5K	–	592
2023 Q1	$34.5K	Sell	1,490 -9,149	-86%	-$218K	0.03%	325
2022 Q4	$279K	Hold	10,639	–	–	0.22%	79
2022 Q3	$209K	Buy	10,639 +1,349	+15%	+$27.1K	0.17%	105
2022 Q2	$162K	Buy	+9,290	New	+$146K	0.13%	145

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

C.M. Bidwell & Associates's KDNY Position: Q2 2023 in Review

C.M. Bidwell & Associates sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 1,490 shares — an estimated $34.5K sold.

C.M. Bidwell & Associates first reported a position in KDNY in Q2 2022 and held it in 4 quarters. The position peaked at $279K in Q4 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

C.M. Bidwell & Associates reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
C.M. Bidwell & Associates sold 1,490 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $34.5K.
C.M. Bidwell & Associates first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
C.M. Bidwell & Associates's Chinook Therapeutics, Inc. Common Stock position peaked at $279K in Q4 2022.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2023, filed 14 Aug 2023.